检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:赵薛斌 赵合庆[1] 邹蓉[1] 张忠文[1] 胡伟东[1]
出 处:《国际脑血管病杂志》2016年第2期163-167,共5页International Journal of Cerebrovascular Diseases
基 金:苏州市科技发展计划(SYS201549)
摘 要:目的:探讨缺血性卒中后癫痫发作复发和耐药性的预测因素。方法回顾性纳入连续的缺血性卒中后首次癫痫发作患者的临床资料,计算癫痫发作复发率及耐药发生率,应用生存分析及 Cox 比例风险模型分析癫痫发作复发和耐药的预测因素。结果共纳入74例连续的缺血性卒中后首次癫痫发作患者,男性45例,女性29例,年龄(66.64±11.50)岁;早发性癫痫发作患者26例,迟发性癫痫发作患者48例。迟发性癫痫发作[优势比(odds ratio, OR)2.56,95%可信区间(confidence interval, CI)1.11~5.88;P =0.027]和部分性发作(OR 3.68,95% CI 1.29~10.48;P =0.015)是缺血性卒中后癫痫发作复发的预测因素;早发性癫痫发作是耐药性的独立预测因素(OR 6.20,95% CI 2.04~18.84;P =0.001)。结论迟发性癫痫发作和部分性发作患者易复发,早发性癫痫发作患者易产生耐药性。Objective To investigate the predictors of recurrence and drug resistance of seizures after ischemic stroke. Methods The clinical data of the consecutive patients w ith the first seizures after ischemic stroke w ere enroled retrospectively. The rates of recurrence and drug resistance of seizures w ere calculated. The survival analysis and Cox proportional hazard model w ere used to analyze the predictors of recurrence and drug resistance of seizures. Results A total of 74 consecutive patients w ith first seizures after ischemic stroke w ere enroled, including 29 w omen and 45 men (aged 66.64 〈11.50 years). There w ere 26 patients w ith early seizures and 48 patients w ith delayed seizures. Delayed seizures (odds ratio [OR] 2.556; 95%confidence interval [CI] 1.11-5.88; P = 0.027) and partial seizures ( OR 3.68, 95% CI 1.29-10.48; P =0.015) w ere the predictors of seizures recurrence after ischemic stroke. Early seizures w as an independent predictor for drug-resistance (OR 6.20, 95% CI 2.04-18.84; P = 0.001). Conclusions The patients w ith delayed seizures and partial seizures are prone to recurrence. The patients w ith early seizures are easy to develop drug-resistance.
分 类 号:R743.3[医药卫生—神经病学与精神病学]
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.222